Total Funding
96
84
Total FundingSeries A raised
Growth Score
12 pts
Heat Score
15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3554
Engitix is operates as a tissue engineering company.
- Giuseppe Mazza: Chief Executive Officer & Co-Founder
- Matthew Edwards: SVP Discovery
About the Company
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for
bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
